CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Revenues:
Finance receivable interest income, including fees	$ 38,439	$ 40,787
Pharmaceutical development	2,153	3,616
Other	865	584
Total revenues	41,457	44,987
Costs and expenses:
Provision for (benefit from) credit losses	(924)	12,756
Loss on impairment	641	5,771
Loss on disposal of inventory	314	0
Interest expense	4,797	4,685
Pharmaceutical manufacturing, research and development expense	1,551	2,203
Change in fair value of acquisition-related contingent consideration	0	(4,900)
Depreciation and amortization expense	40	1,399
General and administrative expense	14,763	11,487
Income from operations	20,275	11,586
Other income (expense), net
Unrealized net gain on warrants	775	2,406
Net gain on exercise and cancellation of warrants	0	445
Loss on sale of assets	(82)	0
Gain on sale of business	1,601	0
Net loss on marketable investments	(384)	(266)
Realized gain on early payment of finance receivables	1,729	1,065
Gain (loss) on revaluation of finance receivables	(3,727)	2,495
Realized and unrealized foreign currency transaction gains (losses)	(71)	641
Income before income tax expense	20,116	18,372
Income tax expense	22,649	4,884
Net income (loss)	$ (2,533)	$ 13,488
Net income (loss) per share
Basic (in dollars per share)	$ (0.21)	$ 1.09
Diluted (in dollars per share)	$ (0.21)	$ 1.09
Weighted average shares outstanding
Basic (in shares)	12,162	12,369
Diluted (in shares)	12,162	12,383